Toxic slobs is more like it.
On going S-3 shelf placement!
Aquestive Therapeutics Announces EPIPHAST II Trial Data For AQST-109; Says 'AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen Tmax of 22.5 minutes'
7:05 am ET September 27, 2022 (Benzinga) Print
AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes
AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration
Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen
End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter
Company hosts conference call at 8:00 am ET on September 27, 2022
Aquestive Therapeutics price target lowered to $7 from $10 at Lake Street
Aquestive Therapeutics price target lowered to $7 from $8 at RBC Capital »
Aquestive Therapeutics price target lowered to $13 from $18 at BMO Capital 07:00 AQST BMO Capital analyst Gary Nachman lowered the firm's price target on Aquestive Therapeutics to $13 from $18 but keeps an Outperform rating on the shares. The analyst notes that the CRL for the company's key product Libervant announced by the FDA on Friday is "disappointing, but should be very fixable" in the near term. Nachman adds that Aquestive intends to resubmit the study by the end of the year and expects a PDUFA date for the drug in the first half of 2021.
Read more at:
Aquestive Therapeutics price target lowered to $17 from $23 at JMP
Aquestive Therapeutics price target lowered to $17 from $23 at JMP Securities 06:07 AQST JMP Securities analyst Jason Butler lowered the firm's price target on Aquestive Therapeutics to $17 from $23 but keeps an Outperform rating on the shares. The analyst notes that the company's announcement of an FDA CRL for Libervant announced on Friday is disappointing, but he believes that the path to approval remains "timely and low risk". Butler adds that his probability of approval for the drug remains at 85%, though his model pushes back assumptions for its launch and first sales by one year to 2021.
Read more at:
It looks like a minor fixable issue. People can sell their shares to me for a sub $4 price and I will scoop them up.
What was discovered were minor issues that will be easily addressed. Read the CRL and you will see that the expected new PDUFA will probably be 1Q 2021. I do hope they do not dilute before then.
12 down days in a row : ( Ironically, last year in July-August, $AQST was 17 days down in a row before their earning pushed it higher.
$3.70-3.80 is possible based on the chart. If you believe in Gap Fills, the 4/13-4/14 fill would give us $3.37 price.
There is nothing fundamentally wrong with the stock. We are just in a dead period with no news so people are selling.
Filled at $4.25. Next buy will be around $4. I need $AQST to form a base before I put a limit order in. It could break into the $3 too.
I hope you guys bought on the dip!
This is going to be big!!!!
This technology is SUCH a big deal for these patient's. The ability to swallow pills, even 00 gel caps (500mg) is a major concern for those that cannot swallow or struggle doing so.
The cherry (please excuse the term) is suboxone, fentanyl (eventually?), and other pain meds that need to be single dosed.
It looks like the chart want to form a base but the volume is predictably drying up.
$4.50 and below is still my buy in.
Amen brother, great buying opportunity, gonna be another run up to PDUFA 9/27/2020
Does Diazepam have a catalyst / PDUFA date set this year?
Is Aquestive looking at all ready approved microgram drugs like Fentanyl, etc.?
I currently own a nice chunk of this stock I will be accumulating in June when the price goes below $4.50. It is my #1 small cap right now and I am holding for 5 + years.
Just thought that the stock would do better.
I am not quite sure i understood what you meant.
Is this it?
Definition of eat humble pie. informal. : to admit that one was wrong or accept that one has been defeated They had to eat humble pie when the rumors they were spreading were proved false.